DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Darifenacin in the treatment of overactive bladder.

Author(s): Parsons M, Robinson D, Cardozo L

Affiliation(s): Department of Urogynaecology, 3rd Floor, Golden Jubilee Wing, King's College Hospital, London, UK. mparsons@doctors.org.uk

Publication date & source: 2005-07, Int J Clin Pract., 59(7):831-8.

Publication type: Review

Antimuscarinic drug therapy has been shown to be effective in the management of patients with symptoms of the overactive bladder syndrome (OAB), but the bothersome antimuscarinic adverse effects of dry mouth, constipation, somnolence and blurred vision often affect compliance with medication. The development of bladder selective M3 specific antagonists offers the possibility of increasing efficacy whilst minimising adverse effects. The M3 specific antagonist solifenacin has recently been marketed, and darifenacin will soon be available. The purpose of this article is to review the pharmacology and clinical trial data available for darifenacin, in addition to examining its role in the treatment of the OBS.

Page last updated: 2007-02-13

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017